Tg Therapeutics (TGTX) EBT (2016 - 2025)
Historic EBT for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $25.9 million.
- Tg Therapeutics' EBT rose 50705.25% to $25.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year increase of 73197.7%. This contributed to the annual value of $25.6 million for FY2024, which is 9594.24% up from last year.
- Latest data reveals that Tg Therapeutics reported EBT of $25.9 million as of Q3 2025, which was up 50705.25% from $30.9 million recorded in Q2 2025.
- In the past 5 years, Tg Therapeutics' EBT registered a high of $113.9 million during Q3 2023, and its lowest value of -$94.0 million during Q4 2021.
- Its 5-year average for EBT is -$25.2 million, with a median of -$36.6 million in 2022.
- Its EBT has fluctuated over the past 5 years, first plummeted by 9625.38% in 2024, then soared by 50705.25% in 2025.
- Tg Therapeutics' EBT (Quarter) stood at -$94.0 million in 2021, then increased by 14.49% to -$80.4 million in 2022, then soared by 82.55% to -$14.0 million in 2023, then skyrocketed by 281.47% to $25.5 million in 2024, then rose by 1.79% to $25.9 million in 2025.
- Its EBT stands at $25.9 million for Q3 2025, versus $30.9 million for Q2 2025 and $5.5 million for Q1 2025.